NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients receiving efzofitimod vs. placebo were steroid-free with a stable/improved King ...

The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...

The pulmonary sarcoidosis treatment landscape is poised for substantial transformation, primarily driven by the development of targeted therapeutics, improved diagnostic approaches, and rising disease ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ATS ...

Results from a phase 1/2 showed that ATYR1923 was safe and well tolerated. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ATYR1923 for the treatment of sarcoidosis.

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development of namilumab for the treatment of sarcoidosis will be discontinued Primary Endpoint Details: ...

Please provide your email address to receive an email when new articles are posted on . A new review published in JAMA highlights the current diagnosis and treatment of pulmonary sarcoidosis. The ...

Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs ...

Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator ...

BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and ...

aTyr Pharma shares have soared as much as 137% this week following notice of a positive clinical trial. An early-stage clinical trial for a treatment addressing pulmonary sarcoidosis showed it was ...